BIOTECHNOLOGY RESEARCH FOR NERVOUS SYSTEM DISORDERS
Huxley Health is a Global Biotechnology Enterprise, Harnessing the Power of Psychedelics to Develop Groundbreaking Therapies for Neuroinflammatory and Neuropsychiatric Disorders.
​
Founded by a Team of Accomplished Entrepreneurs, Scientists, and Academics, Huxley adopts a Targeted, Capital-Efficient, Research Intensive Approach.
In partnership with world leading institutions, Huxley is redefining R&D in the biotechnology and drug discovery sector, leading the way with innovative approaches.
10+
U.S. FILED PATENTS
IP Portfolio Protecting
Novel Compounds and Formulations.
30+
BILLION COMPOUNDS SCREENED
Leading AI-Enhanced Drug Development
4
FEDERAL RESEARCH GRANTS RECEIVED
Maximizing R&D While Reducing Traditional Costs.
OUR APPROACH TO R&D
INNOVATIVE R&D
Transforming Biotech via cutting-edge AI technology driving innovation in development.
DIVERSE EXPERTISE & LEADERSHIP
Huxley is a team of biotech experts, entrepreneurs, and partners from world-leading institutions, coming together to create a unique and groundbreaking approach to drug development.
DIVERSE IP PORTFOLIO
A robust portfolio of I.P. crafted by top-tier scientists and biotech innovators. Our IP showcases cutting-edge advancements in redefining Psychedelic research, offering unique investment opportunities.
BOARD OF DIRECTORS
BRUCE LINTON
Co-Founder & Chairman
FABIAN MONACO
Board Member
JOHN DiGIROLAMO
Board Member
STRATEGIC PARTNERSHIPS
